Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

An evolving landscape – how changing conditioning regimes can improve myelofibrosis transplant outcomes.

View Full Paper
Ask AI
Bookmark
Share

Authors

SCSarah CharrotJCJames D. Cavenagh

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows stem cell transplantation outcomes improve with Flu/Bu/ATG conditioning in myelofibrosis.

Key Points

  • To evaluate how changing conditioning regimens affect transplant outcomes in myelofibrosis patients.
  • Retrospective review of transplant data from 2010 to 2025 at Barts Health NHS Trust.
  • Analysis of patient demographics, conditioning regimens, and survival outcomes.
  • Comparison of overall and event-free survival across different conditioning regimens.
  • 16 patients underwent allogeneic stem cell transplantation.
  • Median overall survival was 42 months; for Flu/Bu/ATG, it reached 80 months.
  • Graft failure occurred in 25% of patients; acute GvHD developed in 50% of cases.

Cite This Study

Charrot et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dcfchttps://doi.org/10.1182/blood-2025-7715
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Superior long-term outcomes with fludarabine and melphalan reduced intensity regimen in older AML/MDS patients undergoing allogeneic stem cell transplantation: An analysis of CIBMTR data2025 · 1 citations
  2. 2Impact of conditioning regimen on outcomes of adolescents and young adults AML patients undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. a study from the acute leukemia working party of the european society for blood and marrow transplantation.2025 · 1 citations
  3. 3Allogeneic hematopoietic stem cell transplantation for hematological malignancies using nonmyeloablative fludarabine, cyclophosphamide, 200 centigray total body irradiation, and post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil for graft-versus-host disease prophylaxis is associated with low non-relapse mortality.2025
  4. 4Improved Outcomes in Myelofibrosis after Allogeneic Stem-Cell Transplantation in the Era of Ruxolitinib Pretreatment and Intensified Conditioning Regimen—Single-Center Analysis2024 · 6 citations
  5. 5Long-term survival outcomes of allo-HCT in AML with fludarabine/melphalan conditioning and tacrolimus/sirolimus GVHD prophylaxis2025